Q-omics provides the consensus-scored TPT1P1 profile across patient tissues and cancer cell-line models. TPT1P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TPT1P1 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, TPT1P1 RNA expression shows 6,067 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, COAD, and STAD as cancer lineages where TPT1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPT1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPT1P1 survival associations across molecular data types. TPT1P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPT1P1 RNA expression–survival associations across cancer types. High TPT1P1 expression shows unfavorable associations in ACC and KICH, but favorable associations in KIRC, THCA, HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TPT1P1 RNA expression.
This table summarizes TPT1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TPT1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPT1P1 shows lower tumor expression in BRCA, UCEC and LUSC and higher tumor expression in COAD, THCA and KIRC. The COAD box plot shows higher TPT1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.324, t-test p = .001).
This table shows molecular features associated with TPT1P1 in patient tissues and cancer cell lines. In patient samples, TPT1P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
